ADRX — ADARx Pharmaceuticals, Inc.

ADRX closed at $17.81 (+1.02%) on Oct 26, 2026. Recent offering filing (S-1MEF, Sep 2026). Float: 52.5M shares. Latest SEC filing: SCHEDULE 13G on Oct 16, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for ADRX in the TickerWise workspace.

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Company profile

• Sector: Industrials
• Industry: Specialty Business Services
• Country: US
• Exchange: NASDAQ
• Employees: 100
• Website: http://www.adarx.com

Latest SEC filings for ADRX

• 2026-10-16SCHEDULE 13G
• 2026-10-02SCHEDULE 13D
• 2026-09-28S-8
• 2026-09-25EFFECT
• 2026-09-24CERT
• 2026-09-243
• 2026-09-243
• 2026-09-243
• 2026-09-243
• 2026-09-243

Latest ADRX news

• 2026-10-01ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering Read article

Related companies

• CTAS — Cintas Corporation
• RELX — RELX Plc
• TRI — Thomson Reuters Corporation
• CPRT — Copart, Inc.
• RBA — RB Global, Inc.
• ULS — UL Solutions Inc.
• RTO — Rentokil Initial plc
• GPN — Global Payments Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.